{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T12:48:58Z","timestamp":1790686138604,"version":"4.1.0"},"reference-count":26,"publisher":"Elsevier BV","issue":"8","license":[{"start":{"date-parts":[[2020,8,1]],"date-time":"2020-08-01T00:00:00Z","timestamp":1596240000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,8,1]],"date-time":"2020-08-01T00:00:00Z","timestamp":1596240000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","clinical-lymphoma-myeloma-leukemia.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Lymphoma Myeloma and Leukemia"],"published-print":{"date-parts":[[2020,8]]},"DOI":"10.1016\/j.clml.2020.03.006","type":"journal-article","created":{"date-parts":[[2020,3,19]],"date-time":"2020-03-19T21:12:50Z","timestamp":1584652370000},"page":"e506-e512","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":19,"title":["Long-term Hodgkin Lymphoma Survivors: A Glimpse of What Happens 10 Years After Treatment"],"prefix":"10.1016","volume":"20","author":[{"given":"Filomena Emanuela","family":"Laddaga","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marco","family":"Moschetta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tommasina","family":"Perrone","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sebastio","family":"Perrini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paolo","family":"Colonna","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giuseppe","family":"Ingravallo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dario","family":"D\u2019abbicco","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giorgina","family":"Specchia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7817-1665","authenticated-orcid":false,"given":"Francesco","family":"Gaudio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.clml.2020.03.006_bib1","doi-asserted-by":"crossref","first-page":"707542","DOI":"10.1155\/2011\/707542","article-title":"Outcome of very late relapse in patients with Hodgkin\u2019s lymphomas","volume":"2011","author":"Gaudio","year":"2011","journal-title":"Adv Hematol"},{"key":"10.1016\/j.clml.2020.03.006_bib2","doi-asserted-by":"crossref","first-page":"2101","DOI":"10.1200\/JCO.2002.08.021","article-title":"Long-term survival and competing causes of death in patients with early-stage Hodgkin\u2019s disease treated at age 50 or younger","volume":"20","author":"Ng","year":"2002","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.clml.2020.03.006_bib3","doi-asserted-by":"crossref","first-page":"1632","DOI":"10.1016\/j.ejca.2010.02.010","article-title":"Mortality is persistently increased in Hodgkin\u2019s lymphoma survivors","volume":"46","author":"Kiserud","year":"2010","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.clml.2020.03.006_bib4","doi-asserted-by":"crossref","first-page":"3431","DOI":"10.1200\/JCO.2003.07.131","article-title":"Long-term cause-specific mortality of patients treated for Hodgkin\u2019s disease","volume":"21","author":"Aleman","year":"2003","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.clml.2020.03.006_bib5","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1053\/j.seminhematol.2016.05.008","article-title":"Hodgkin lymphoma: late effects of treatment and guidelines for surveillance","volume":"53","author":"Ng","year":"2016","journal-title":"Semin Hematol"},{"key":"10.1016\/j.clml.2020.03.006_bib6","doi-asserted-by":"crossref","first-page":"488","DOI":"10.1002\/ijc.10981","article-title":"Health profiles in 5836 long-term cancer survivors","volume":"104","author":"Schultz","year":"2003","journal-title":"Int J Cancer"},{"key":"10.1016\/j.clml.2020.03.006_bib7","doi-asserted-by":"crossref","first-page":"993","DOI":"10.1007\/s00277-011-1274-4","article-title":"The impact of treatment, socio-demographic and clinical characteristics on health- related quality of life among Hodgkin\u2019s and non-Hodgkin\u2019s lymphoma survivors: a systematic review","volume":"90","author":"Oerlemans","year":"2011","journal-title":"Ann Hematol"},{"key":"10.1016\/j.clml.2020.03.006_bib8","doi-asserted-by":"crossref","first-page":"1596","DOI":"10.3109\/10428194.2013.854889","article-title":"Peripheral blood CD4\/CD19 cell ratio is an independent prognostic factor in classical Hodgkin lymphoma","volume":"55","author":"Gaudio","year":"2014","journal-title":"Leuk Lymphoma"},{"key":"10.1016\/j.clml.2020.03.006_bib9","doi-asserted-by":"crossref","first-page":"e261","DOI":"10.1016\/j.clml.2018.04.001","article-title":"Extralymphatic disease is an independent prognostic factor in Hodgkin lymphoma","volume":"18","author":"Gaudio","year":"2018","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"10.1016\/j.clml.2020.03.006_bib10","doi-asserted-by":"crossref","first-page":"1817","DOI":"10.1007\/s00277-018-3379-5","article-title":"Brentuximab vedotin as salvage treatment in Hodgkin lymphoma na\u00efve transplant patients or failing ASCT: the real life experience of Rete Ematologica Pugliese (REP)","volume":"97","author":"Pavone","year":"2018","journal-title":"Ann Hematol"},{"key":"10.1016\/j.clml.2020.03.006_bib11","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1016\/j.clml.2018.08.012","article-title":"Outcomes of reduced intensity conditioning allogeneic hematopoietic stem cell transplantation for Hodgkin lymphomas: a retrospective multicenter experience by the Rete Ematologica Pugliese (REP)","volume":"19","author":"Gaudio","year":"2019","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"10.1016\/j.clml.2020.03.006_bib12","doi-asserted-by":"crossref","first-page":"2499","DOI":"10.1056\/NEJMoa1505949","article-title":"Second cancer risk up to 40 years after treatment for Hodgkin\u2019s lymphoma","volume":"373","author":"Schaapveld","year":"2015","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.clml.2020.03.006_bib13","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1182\/blood-2013-10-532184","article-title":"Risk of multiple primary malignancies following treatment of Hodgkin lymphoma","volume":"124","author":"van Eggermond","year":"2014","journal-title":"Blood"},{"key":"10.1016\/j.clml.2020.03.006_bib14","doi-asserted-by":"crossref","first-page":"1489","DOI":"10.1200\/JCO.2006.09.0936","article-title":"Long-term solid cancer risk among 5-year survivors of Hodgkin\u2019s lymphoma","volume":"25","author":"Hodgson","year":"2007","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.clml.2020.03.006_bib15","doi-asserted-by":"crossref","first-page":"1584","DOI":"10.1200\/JCO.2016.70.9709","article-title":"Risk of second cancer in Hodgkin lymphoma survivors and influence of family history","volume":"35","author":"Sud","year":"2017","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.clml.2020.03.006_bib16","doi-asserted-by":"crossref","first-page":"1007","DOI":"10.1001\/jamainternmed.2015.1180","article-title":"Cardiovascular disease after Hodgkin lymphoma treatment: 40-year disease risk","volume":"175","author":"van Nimwegen","year":"2015","journal-title":"JAMA Intern Med"},{"key":"10.1016\/j.clml.2020.03.006_bib17","doi-asserted-by":"crossref","first-page":"e492","DOI":"10.1016\/S2352-3026(15)00153-2","article-title":"Cardiovascular disease after treatment for Hodgkin\u2019s lymphoma: an analysis of nine collaborative EORTC-LYSA trials","volume":"2","author":"Maraldo","year":"2015","journal-title":"Lancet Haematol"},{"key":"10.1016\/j.clml.2020.03.006_bib18","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1093\/oxfordjournals.annonc.a059221","article-title":"Lung function impairment in long-term survivors of Hodgkin's disease","volume":"6","author":"Lund","year":"1995","journal-title":"Ann Oncol"},{"key":"10.1016\/j.clml.2020.03.006_bib19","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1007\/s00277-011-1255-7","article-title":"Low incidence of long-term respiratory impairment in Hodgkin lymphoma survivors","volume":"91","author":"Avivi","year":"2012","journal-title":"Ann Hematol"},{"key":"10.1016\/j.clml.2020.03.006_bib20","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1002\/1097-0142(19910815)68:4<699::AID-CNCR2820680406>3.0.CO;2-5","article-title":"Drug-related pulmonary toxicity in non-Hodgkin\u2019s lymphoma. Comparative results with three different treatment regimens","volume":"68","author":"Shapiro","year":"1991","journal-title":"Cancer"},{"key":"10.1016\/j.clml.2020.03.006_bib21","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1634\/theoncologist.1-1-62","article-title":"Thyroid abnormalities after therapy for Hodgkin\u2019s disease in childhood","volume":"1","author":"Bhatia","year":"1996","journal-title":"Oncologist"},{"key":"10.1016\/j.clml.2020.03.006_bib22","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1200\/JCO.2011.37.1989","article-title":"Premature ovarian failure and fertility in long-term survivors of Hodgkin\u2019s lymphoma: a European Organisation for Research and Treatment of Cancer Lymphoma Group and Groupe d\u2019Etude des Lymphomes de l\u2019Adulte Cohort Study","volume":"30","author":"van der Kaaij","year":"2012","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.clml.2020.03.006_bib23","doi-asserted-by":"crossref","first-page":"2825","DOI":"10.1200\/JCO.2006.10.2020","article-title":"Gonadal function in males after chemotherapy for early-stage Hodgkin\u2019s lymphoma treated in four subsequent trials by the European Organisation for Research and Treatment of Cancer: EORTC Lymphoma Group and the Groupe d\u2019Etude des Lymphomes de l\u2019Adulte","volume":"25","author":"van der Kaaij","year":"2007","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.clml.2020.03.006_bib24","doi-asserted-by":"crossref","first-page":"1947","DOI":"10.1007\/s00277-019-03684-0","article-title":"Pregnancy rate and outcome of pregnancies in long-term survivors of Hodgkin\u2019s lymphoma","volume":"98","author":"Gaudio","year":"2019","journal-title":"Ann Hematol"},{"key":"10.1016\/j.clml.2020.03.006_bib25","doi-asserted-by":"crossref","first-page":"6587","DOI":"10.1200\/JCO.2005.09.936","article-title":"Fatigue in long-term Hodgkin\u2019s disease survivors: a follow-up study","volume":"23","author":"Hjermstad","year":"2005","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.clml.2020.03.006_bib26","doi-asserted-by":"crossref","first-page":"1023","DOI":"10.1007\/s00277-013-1793-2","article-title":"Persisting fatigue in Hodgkin lymphoma survivors: a systematic review","volume":"92","author":"Daniels","year":"2013","journal-title":"Ann Hematol"}],"container-title":["Clinical Lymphoma Myeloma and Leukemia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2152265020301397?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2152265020301397?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T00:34:45Z","timestamp":1761870885000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2152265020301397"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,8]]},"references-count":26,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2020,8]]}},"alternative-id":["S2152265020301397"],"URL":"https:\/\/doi.org\/10.1016\/j.clml.2020.03.006","relation":{},"ISSN":["2152-2650"],"issn-type":[{"value":"2152-2650","type":"print"}],"subject":[],"published":{"date-parts":[[2020,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Long-term Hodgkin Lymphoma Survivors: A Glimpse of What Happens 10 Years After Treatment","name":"articletitle","label":"Article Title"},{"value":"Clinical Lymphoma Myeloma and Leukemia","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clml.2020.03.006","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}